This trial looks at the safety of using the drug tazemetostat with other treatments for blood cancer. Tazemetostat has been found to be a safe and effective drug for patients with relapsed refractory follicular lymphoma. Giving tazemetostat in combination with other treatments may work better in treating patients with blood cancer and may improve disease response and durability of response.
2 Primary · 3 Secondary · Reporting Duration: Time from the date of first dose of study drug to the time of response, assessed up to 24 months
156 Total Participants · 9 Treatment Groups
Primary Treatment: Arm 5-Tazemetostat plus mosunetuzumab (CD20/CD3 BsAb) in subjects with R/R follicular lymphoma · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: